{"filing":{"accession_number":"0001690585-26-000026","cik":"0001690585","ticker":"DNTH","company_name":"Dianthus Therapeutics, Inc. /DE/","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"dnth-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1690585/000169058526000026/dnth-20260521.htm"},"events":[{"id":10729,"run_id":9411,"accession_number":"0001690585-26-000026","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear Item 5.07 disclosure of shareholder vote results from Dianthus Therapeutics' Annual Meeting of Stockholders held on May 21, 2026. The filing presents final voting tallies for three proposals: election of Class II directors (Sujay Kango, Anne McGeorge, and Jonathan Violin, Ph.D.), advisory approval of executive compensation, and ratification of Deloitte \u0026 Touche, LLP as independent auditor. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and shareholder sentiment.","company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","filing_date":"2026-05-22","form":"8-K","submitted_at":null,"items":[{"id":7114,"accession_number":"0001690585-26-000026","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder vote results from Dianthus Therapeutics' Annual Meeting of Stockholders held on May 21, 2026. The filing presents final voting tallies for three proposals: election of Class II directors (Sujay Kango, Anne McGeorge, and Jonathan Violin, Ph.D.), advisory approval of executive compensation, and ratification of Deloitte \u0026 Touche, LLP as independent auditor. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and shareholder sentiment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:58:53.212368+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7114,"accession_number":"0001690585-26-000026","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder vote results from Dianthus Therapeutics' Annual Meeting of Stockholders held on May 21, 2026. The filing presents final voting tallies for three proposals: election of Class II directors (Sujay Kango, Anne McGeorge, and Jonathan Violin, Ph.D.), advisory approval of executive compensation, and ratification of Deloitte \u0026 Touche, LLP as independent auditor. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and shareholder sentiment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:58:53.212368+00:00","company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","filing_date":"2026-05-22"}]}